April 2, 2019 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2018, which is earlier than indicated in the financial calendar. The Annual Report (in the Swedish language) is attached as a PDF and is available on the company’s website, www.indexpharma.com.
The printed Annual Report is mailed to shareholders and other stakeholders who specifically request it. Send request to [email protected], or by mail to InDex Pharmaceuticals Holding AB (publ), Tomtebodavägen 23a, 171 77 Stockholm.
For more information:
Peter Zerhouni, CEO
Phone: +46 8 508 847 35
E-mail: [email protected]
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Stockholm. Redeye AB with email address [email protected] och phone number +46 8 121 576 90 is the company’s Certified Adviser. For more information, please visit www.indexpharma.com.
Publication
The information was submitted for publication at 17:30 CET on April 2, 2019.
